Aura Biosciences Financials
| AURA Stock | USD 9.31 0.31 3.44% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 11.37 | 18.7581 |
|
|
Investors should never underestimate Aura Biosciences' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Aura Biosciences' cash flow, debt, and profitability to make informed and accurate decisions about investing in Aura Biosciences.
Net Income |
|
Aura | Select Account or Indicator |
Understanding current and past Aura Biosciences Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Aura Biosciences' financial statements are interrelated, with each one affecting the others. For example, an increase in Aura Biosciences' assets may result in an increase in income on the income statement.
Please note, the presentation of Aura Biosciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Aura Biosciences' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Aura Biosciences' management manipulating its earnings.
Aura Biosciences Stock Summary
Aura Biosciences competes with Aerovate Therapeutics, Adagene, Acrivon Therapeutics,, Rezolute, and AN2 Therapeutics. Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts. Aura Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 52 people.| Foreign Associates | |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US05153U1079 |
| CUSIP | 05153U107 |
| Location | Massachusetts; U.S.A |
| Business Address | 80 Guest Street, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.aurabiosciences.com |
| Phone | 617 500 8864 |
| Currency | USD - US Dollar |
Aura Biosciences Key Financial Ratios
| Return On Equity | -0.51 | ||||
| EBITDA | (83.7 M) | ||||
| Net Income | (76.41 M) | ||||
| Cash Per Share | 4.17 X | ||||
| Debt To Equity | 0.01 % |
Aura Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Aura Biosciences's current stock value. Our valuation model uses many indicators to compare Aura Biosciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Aura Biosciences competition to find correlations between indicators driving Aura Biosciences's intrinsic value. More Info.Aura Biosciences is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . At present, Aura Biosciences' Return On Equity is projected to slightly decrease based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Aura Biosciences' earnings, one of the primary drivers of an investment's value.Aura Biosciences Systematic Risk
Aura Biosciences' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Aura Biosciences volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was ten with a total number of output elements of fifty-one. The Beta measures systematic risk based on how returns on Aura Biosciences correlated with the market. If Beta is less than 0 Aura Biosciences generally moves in the opposite direction as compared to the market. If Aura Biosciences Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Aura Biosciences is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Aura Biosciences is generally in the same direction as the market. If Beta > 1 Aura Biosciences moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Aura Biosciences Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Aura Biosciences' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Aura Biosciences growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Aura Biosciences November 30, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Aura Biosciences help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Aura Biosciences. We use our internally-developed statistical techniques to arrive at the intrinsic value of Aura Biosciences based on widely used predictive technical indicators. In general, we focus on analyzing Aura Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Aura Biosciences's daily price indicators and compare them against related drivers.
| Downside Deviation | 2.99 | |||
| Information Ratio | 0.0479 | |||
| Maximum Drawdown | 19.11 | |||
| Value At Risk | (4.95) | |||
| Potential Upside | 7.71 |
Complementary Tools for Aura Stock analysis
When running Aura Biosciences' price analysis, check to measure Aura Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aura Biosciences is operating at the current time. Most of Aura Biosciences' value examination focuses on studying past and present price action to predict the probability of Aura Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aura Biosciences' price. Additionally, you may evaluate how the addition of Aura Biosciences to your portfolios can decrease your overall portfolio volatility.
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |